Aligos Therapeutics shares are trading higher after HC Wainwright & Co initiated coverage on the stock with a Buy rating and announced a price target of $75.
Portfolio Pulse from Benzinga Newsdesk
Aligos Therapeutics shares rose after HC Wainwright & Co initiated coverage with a Buy rating and set a price target of $75.
August 19, 2024 | 2:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aligos Therapeutics shares increased following HC Wainwright & Co's initiation of coverage with a Buy rating and a $75 price target.
The initiation of coverage by a reputable firm like HC Wainwright & Co with a Buy rating and a high price target is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100